Methods for Improving Pancreatic Islet Transplantation

Information

  • Research Project
  • 6735494
  • ApplicationId
    6735494
  • Core Project Number
    R41DK064424
  • Full Project Number
    1R41DK064424-01A1
  • Serial Number
    64424
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2004 - 20 years ago
  • Project End Date
    7/31/2005 - 19 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    8/1/2004 - 20 years ago
  • Budget End Date
    7/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/19/2004 - 20 years ago
Organizations

Methods for Improving Pancreatic Islet Transplantation

[unreadable] DESCRIPTION (provided by applicant): [unreadable] Transplantation of islets of Langerhans has long held promise as a cure for Type 1 diabetes mellitus. In the past, most islet transplants failed to achieve insulin independence. Recently, a new immunosuppressant protocol developed at Edmonton, Canada has significantly improved the success rate of islet transplantation. Nevertheless, there remain serious problems that negatively impact the outcome of islet transplantation. Reduced islet viability due to the trauma of isolation has made it necessary to use multiple donors to achieve insulin independence in a single recipient. The loss of supporting cells and extracellular matrix also contributes to transplant failure. Some progress has been made in addressing these problems by culturing islets in vitro before transplantation, allowing some recovery of islet viability. In this application, we propose to use a new culture technique employing a simulated microgravity bioreactor developed at NASA to dramatically improve islet culture and thereby increase islet viability after transplantation. The specific aims of phase I are: 1. To construct a modified perfused Rotary Cell Culture System (RCCS) to maintain islets in a carefully controlled physiological environment to improve viability. (a) Use automated media changes to maintain physiological pH and glucose levels. (b) Use automated infusions of growth factors and other biochemical agents to help sustain normal islet function. 2. To assess in vitro islet structure and viability in the RCCS compared to conventional static culture. (a) Structural integrity assessed by immunohistochemistry. (b) Function assessed by secretagogue-stimulated hormone secretion. (c) Viability assessed by a battery of assays. After optimization of islet culture in the perfused RCCS using rat islets in phase I, the procedures will be applied to human islets in phase II and tested in an animal model of diabetes. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R41
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100170
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100170\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SYNTHECON, INC.
  • Organization Department
  • Organization DUNS
    809505225
  • Organization City
    HOUSTON
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77054
  • Organization District
    UNITED STATES